Redacid (cinnamomum burmannii) / Dexa Medica Group - LARVOL DELTA

DLBS2411 Treatment for Functional Dyspepsia (clinicaltrials.gov) - P3 | N=106 | Recruiting | Sponsor: Dexa Medica Group | Trial completion date: Apr 2025 ➔ Aug 2025 | Trial primary completion date: Feb 2025 ➔ Jun 2025

Trial completion date • Trial primary completion date • Dyspepsia

DLBS2411 Treatment For Functional Dyspepsia (clinicaltrials.gov) - P3 | N=100 | Recruiting | Sponsor: Dexa Medica Group | Trial completion date: Jun 2024 ➔ Apr 2025 | Trial primary completion date: Apr 2024 ➔ Dec 2024

Trial completion date • Trial primary completion date • Dyspepsia

DLBS2411 Treatment For Functional Dyspepsia (clinicaltrials.gov) - P3 | N=100 | Recruiting | Sponsor: Dexa Medica Group | Not yet recruiting ➔ Recruiting

Enrollment open • Dyspepsia

DLBS2411 Treatment For Functional Dyspepsia (clinicaltrials.gov) - P3 | N=100 | Not yet recruiting | Sponsor: Dexa Medica Group | Initiation date: Mar 2022 ➔ Dec 2022

Trial initiation date • Dyspepsia

DLBS2411 Treatment For Functional Dyspepsia (clinicaltrials.gov) - P3 | N=100 | Not yet recruiting | Sponsor: Dexa Medica Group

New P3 trial • Dyspepsia

Efficacy and Safety of DLBS2411 in the Management of GERD (clinicaltrials.gov) - P3; N=32; Terminated; Sponsor: Dexa Medica Group; The Study Site classifies as tertiary referral hospital. Therefore, GERD Patients being referred to the site are mostly those with comorbidities included in the exclusion criteria.

Clinical • Enrollment change • Trial primary completion date • Trial termination • Gastroenterology • Gastroesophageal Reflux Disease

Gastroprotective Effect of DLBS2411 Bioactive Fraction from Cinnamomum burmannii Against Ethanol-Induced Gastric Damage in Rats. (PubMed, J Exp Pharmacol) - "The rats were divided into five treatment groups, which were the Normal control group, Negative control group (ethanol-induced) and two treatment groups: DLBS2411 at the doses of 25 mg/kg body weight (BW) and 50 mg/kg BW, and the Positive control group treated with sucralfate at the dose of 100 mg/kg BW. Histopathological data showed that gastric epithelial cells in the Negative control group were more severely ulcerated than in the treatment group of DLBS2411 and the Positive control group. This study showed that DLBS2411 at the dose of 50 mg/kg BW was more effective in protecting the stomach lining than DLBS2411 at the dose of 25 mg/kg BW, as measured by percentage of ulceration inhibition and the ulcerative lesion index."

Journal • Preclinical

DLBS2411 Treatment for Ulcer Healing in Non-Bleeding Peptic Ulcers (clinicaltrials.gov) - P3; N=32; Terminated; Sponsor: Dexa Medica Group; Trial completion date: Aug 2019 ➔ Mar 2019; Active, not recruiting ➔ Terminated; Trial primary completion date: Jun 2019 ➔ Feb 2019; This study was terminated due to internal technical issues at study site

Trial completion date • Trial primary completion date • Trial termination

DLBS2411 Treatment for Ulcer Healing in Non-Bleeding Peptic Ulcers (clinicaltrials.gov) - P3; N=32; Active, not recruiting; Sponsor: Dexa Medica Group; Recruiting ➔ Active, not recruiting

Enrollment closed

Efficacy and Safety of DLBS2411 in the Management of GERD (clinicaltrials.gov) - P3; N=258; Recruiting; Sponsor: Dexa Medica Group; Active, not recruiting ➔ Recruiting; Trial completion date: Dec 2018 ➔ Dec 2020; Initiation date: Nov 2017 ➔ Aug 2018; Trial primary completion date: Oct 2018 ➔ Oct 2020

Clinical • Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date